My Experience with Peptides | Page 3 | The Forum

"Companies have funded clinical trials, but in the case of BPC 157, they abandoned it before any results were published. No reasons given."

The above cited articles, you are right, were far less rigorous than your profound generic statement above.

JohnK is right though, the statistical reality that ninety percent of drugs tested in mice fail to reach the market is true, yet applying this figure as a blanket rule ignores the efficacy of different families of drugs. Certain biological pathways demonstrate a much higher rate of translational success from mice to humans. In connective tissue research, the cellular mechanics of collagen synthesis and tendon repair are fundamentally similar across most mammalian species. Unlike complex cognitive functions or unique inflammatory responses that vary wildly, the way a fibroblast responds to a healing stimulus is a highly conserved trait. When targeting these specific families of drugs, the murine model (using mice or rats) remains a reliable predictor of human outcomes because the basic physics of tissue repair does not change significantly between species.

The practical utility of a biological model is ultimately secondary to the economic incentives that dictate which drugs receive funding. The pharmaceutical industry operates under a mandate for recurring revenue, which frequently steers research away from genuine healthspan extension and toward the management of chronic conditions. A significant portion of development capital is directed into medications that mitigate the consequences of poor health choices rather than those that optimize human biology or provide curative regeneration. This profit driven approach means that even when the science is sound and the animal trials are promising, a drug may never reach the public if it does not fit a lucrative business model.

The current medical establishment operates primarily from a framework of chronic disease management rather than definitive cure. While a growing number of practitioners are integrating compounds like BPC 157 into their clinical protocols to address tissue repair, these efforts remain outside the mainstream standard of care, but are growing.

You may have a blind faith in the current medical model, but I put my trust of doctors and big pharma slightly higher than politicians and lawyers. Especially when you consider through incompentence of practice they are the third leading cause of death in the US. Here is a study by Makary, M. A., & Daniel, M. (2016). Medical error—the third leading cause of death in the US. BMJ, 353, i2139. doi:10.1136/bmj.i2139. In this analysis, researchers from Johns Hopkins University School of Medicine estimated that medical error accounts for over 250,000 deaths annually in the United States.

As an engineer, I find those figures ridiculous. If the engineering profession saw that level of loss of life, the entire industry would be under federal investigation and the individuals responsible would be behind bars. In our field, a single structural collapse or plane crash is a national tragedy; in medicine, 200,000 deaths are often treated as a statistical byproduct of the system or "medical error."